Antiretroviral therapy coverage for PMTCT in Honduras

Honduras: Antiretroviral therapy coverage for PMTCT was 42.0% in 2024. ◆ Volatile

Latest (2024)
42.0%
Change on year
down 17.6%
World rank
70th
of 84 countries
All-time high
55.0%
in 2018
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Antiretroviral therapy coverage for PMTCT in Honduras, 2000–2024

02040602000201220242000: 0 % of pregnant women living with HIV2001: 0 % of pregnant women living with HIV2002: 0 % of pregnant women living with HIV2003: 3 % of pregnant women living with HIV2004: 7 % of pregnant women living with HIV2005: 12 % of pregnant women living with HIV2006: 18 % of pregnant women living with HIV2007: 25 % of pregnant women living with HIV2008: 26 % of pregnant women living with HIV2009: 45 % of pregnant women living with HIV2010: 41 % of pregnant women living with HIV2011: 42 % of pregnant women living with HIV2012: 47 % of pregnant women living with HIV2013: 44 % of pregnant women living with HIV2014: 45 % of pregnant women living with HIV2015: 42 % of pregnant women living with HIV2016: 44 % of pregnant women living with HIV2017: 47 % of pregnant women living with HIV2018: 55 % of pregnant women living with HIV2019: 44 % of pregnant women living with HIV2020: 39 % of pregnant women living with HIV2021: 43 % of pregnant women living with HIV2022: 43 % of pregnant women living with HIV2023: 51 % of pregnant women living with HIV2024: 42 % of pregnant women living with HIV

Source: UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS). Measured in % of pregnant women living with HIV.

Analysis

In 2024, antiretroviral therapy coverage for pmtct in Honduras stood at 42.0%.

The figure is down 17.6% on the previous year and down 6.7% over ten years.

Over the whole period, antiretroviral therapy coverage for pmtct in Honduras peaked at 55.0% in 2018 and was at its lowest, 0.0%, in 2000.

Honduras ranks 70th of 84 countries on this measure, in the bottom quarter.

The series is highly variable year to year, so single readings are best treated with caution.

Antiretroviral therapy coverage for PMTCT in Honduras, year by year

Annual values for Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV) in Honduras, 2000 to 2024.
Year % of pregnant women living with HIV Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 3.0%
2004 7.0% +133.3%
2005 12.0% +71.4%
2006 18.0% +50.0%
2007 25.0% +38.9%
2008 26.0% +4.0%
2009 45.0% +73.1%
2010 41.0% -8.9%
2011 42.0% +2.4%
2012 47.0% +11.9%
2013 44.0% -6.4%
2014 45.0% +2.3%
2015 42.0% -6.7%
2016 44.0% +4.8%
2017 47.0% +6.8%
2018 55.0% +17.0%
2019 44.0% -20.0%
2020 39.0% -11.4%
2021 43.0% +10.3%
2022 43.0% +0.0%
2023 51.0% +18.6%
2024 42.0% -17.6%

Honduras compared with similar countries

  • Honduras's 42.0% is below the median for lower middle income countries, which is 83.5%, 50% of the median. (32 countries reporting)
  • Honduras's 42.0% is below the median for Latin America & Caribbean, which is 68.0%, 62% of the median. (15 countries reporting)

Biggest year-on-year movements

Years where Antiretroviral therapy coverage for PMTCT in Honduras changed far more than this series normally does. A large move can be a real event or a change in how the figure was measured — the source note below says who published it.

YearChange FromTo
2004 +133.3% 3.0% 7.0%

Averages by decade

DecadeAverage LowestHighest Years
2000s 13.6% 0.0% 45.0% 10
2010s 45.1% 41.0% 55.0% 10
2020s 43.6% 39.0% 51.0% 5

Countries ranked near Honduras

  1. 67 Paraguay 52.0% compare
  2. 68 Mali 46.0% compare
  3. 69 Somalia 43.0% compare
  4. 70 Congo 42.0% compare
  5. 70 Costa Rica 42.0% compare
  6. 73 Mauritania 39.0% compare

See the full ranking of 99 places →

More health data for Honduras

All data for Honduras →

Frequently asked questions

What is antiretroviral therapy coverage for pmtct in Honduras?
Antiretroviral therapy coverage for pmtct in Honduras was 42.0% in 2024, according to UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS).
What is the highest antiretroviral therapy coverage for pmtct recorded in Honduras?
The highest recorded value was 55.0% in 2018.
What is the lowest antiretroviral therapy coverage for pmtct recorded in Honduras?
The lowest recorded value was 0.0% in 2000.
How does Honduras rank for antiretroviral therapy coverage for pmtct?
Honduras ranks 70th out of 84 countries with data for 2024.
Is antiretroviral therapy coverage for pmtct rising or falling in Honduras?
Over the last ten years it is down 6.7%. The long-run trend across the full record is volatile.
Where does this Honduras data come from?
The figures come from UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as part of Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Antiretroviral therapy coverage for PMTCT in Honduras. Statizoid, drawing on UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS). Retrieved 18 September 2026, from https://health.statizoid.com/stat/antiretroviral-therapy-coverage-for-pmtct-percent-of-pregnant-women-living-with-hiv/honduras/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://health.statizoid.com/stat/antiretroviral-therapy-coverage-for-pmtct-percent-of-pregnant-women-living-with-hiv/honduras/">Antiretroviral therapy coverage for PMTCT in Honduras</a> — Statizoid

About this data

Indicator
Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV)
Unit
% of pregnant women living with HIV
Source
UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS)
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
99 places, 2,393 data points, 2000–2024
Last refreshed

Percentage of pregnant women with HIV who receive antiretroviral medicine for prevention of mother-to-child transmission (PMTCT).